BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5

Nature Communications

Volumn 6, Issue , 2015, Pages

  Qin, Junying ^a,b   Zhou, Zhongmei ^a   Chen, Wenlin ^c   Wang, Chunyan ^a,b,c   Zhang, Hailin ^a   Ge, Guangzhe ^a,d   Shao, Ming ^a,d   You, Dingyun ^c   Fan, Zhixiang ^c   Xia, Houjun ^a   Liu, Rong ^a   Chen, Ceshi ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BAP1 PROTEIN; HOST CELL FACTOR C1; KRUPPEL LIKE FACTOR 5; MESSENGER RNA; MULTIPROTEIN COMPLEX; MYC PROTEIN; PROTEIN P27; SMALL INTERFERING RNA; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENOME; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER GROWTH; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DEUBIQUITINATION; EMBRYO; FEMALE; GENE EXPRESSION; GENE LIBRARY; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; WESTERN BLOTTING; BREAST TUMOR; CELL CYCLE; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASM METASTASIS; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UBIQUITINATION;

EID: 84942903789     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9471     Document Type: Article

References (67)

1. Siegel, R., Naishadham, D., Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Di Cosimo, S., Baselga, J. Management of breast cancer with targeted agents: importance of heterogeneity. Nat. Rev. Clin. Oncol. 7, 139-147 (2010).
3. Hurvitz, S. A., Finn, R. S. What's positive about 'triple-negative' breast cancer? Future Oncol. 5, 1015-1025 (2009).
4. Elias, A. D. Triple-negative breast cancer: a short review. Am. J. Clin. Oncol. 33, 637-645 (2010).
5. Lipkowitz, S., Weissman, A. M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 11, 629-643 (2011).
6. Vucic, D., Dixit, V. M., Wertz, I. E. Ubiquitylation in apoptosis: a posttranslational modification at the edge of life and death. Nat. Rev. Mol. Cell Biol. 12, 439-452 (2011).
7. Hershko, A., Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425-479 (1998).
8. Welchman, R. L., Gordon, C., Mayer, R. J. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6, 599-609 (2005).
9. Sowa, M. E. et al. Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389-403 (2009).
10. Nijman, S. M. et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786 (2005).
11. Luise, C. et al. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS ONE 6, e15891 (2011).
12. Sacco, J. J. et al. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 62, 140-157 (2010).
13. Fraile, J. M. et al. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 31, 2373-2388 (2012).
14. Oosterkamp, H. M. et al. USP9X downregulation renders breast cancer cells resistant to tamoxifen. Cancer Res. 74, 3810-3820 (2014).
15. Harhaj, E. W., Dixit, V. M. Deubiquitinases in the regulation of NF-kappaB signaling. Cell Res. 21, 22-39 (2011).
16. Goldenberg, S. J. et al. Strategies for the identification of novel inhibitors of deubiquitinating enzymes. Biochem. Soc. Trans. 36(Pt 5): 828-832 (2008).
17. Nicholson, B. et al. Deubiquitinating enzymes as novel anticancer targets. Future Oncol. 3, 191-199 (2007).
18. Kapuria, V. et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 70, 9265-9276 (2010).
19. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008).
20. Tong, D. et al. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin. Cancer Res. 12, 2442-2448 (2006).
21. Takagi, K. et al. Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocr. Relat. Cancer 19, 741-750 (2012).
22. Chen, C. et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int. J. Cancer 118, 1346-1355 (2006).
23. Zheng, H. Q. et al. Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Oncogene 28, 3702-3713 (2009).
24. Liu, R. et al. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J. Biol. Chem. 284, 16791-16798 (2009).
25. Xia, H. et al. Kruppel-like factor 5 transcription factor promotes microsomal prostaglandin E2 synthase 1 gene transcription in breast cancer. J. Biol. Chem. 288, 26731-26740 (2013).
26. Chen, C. et al. Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 24, 3319-3327 (2005).
27. Chen, C. et al. Proteasomal degradation of the KLF5 transcription factor through a ubiquitin-independent pathway. FEBS Lett. 581, 1124-1130 (2007).
28. Chen, C. et al. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J. Biol. Chem. 280, 41553-41561 (2005).
29. Zhao, D. et al. The Fbw7 tumor suppressor targets KLF5 for ubiquitinmediated degradation and suppresses breast cell proliferation. Cancer Res. 70, 4728-4738 (2010).
30. Du, J. X. et al. The E3 ubiquitin ligase SMAD ubiquitination regulatory factor 2 negatively regulates Kruppel-like factor 5 protein. J. Biol. Chem. 286, 40354-40364 (2011).
31. Ventii, K. H. et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 68, 6953-6962 (2008).
32. Nishikawa, H. et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 69, 111-119 (2009).
33. Machida, Y. J. et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J. Biol. Chem. 284, 34179-34188 (2009).
34. Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153-159 (2013).
35. Jensen, D. E. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097-1112 (1998).
36. Goldstein, A. M. Germline BAP1 mutations and tumor susceptibility. Nat. Genet. 43, 925-926 (2011).
37. Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668-672 (2011).
38. Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022-1025 (2011).
39. Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413 (2010).
40. Wiesner, T. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018-1021 (2011).
41. Pena-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751-759 (2012).
42. Dey, A. et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337, 1541-1546 (2012).
43. Misaghi, S. et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol. Cell. Biol. 29, 2181-2192 (2009).
44. Mashtalir, N. et al. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol. Cell 54, 392-406 (2014).
45. Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243-247 (2010).
46. Yu, H. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol. Cell. Biol. 30, 5071-5085 (2010).
47. Weigelt, B., Peterse, J. L., van't Veer, L. J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602 (2005).
48. Ewens, K. G. et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 55, 5160-5167 (2014).
49. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
50. Chen, C. et al. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21, 6567-6572 (2002).
51. Lelekakis, M. et al. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17, 163-170 (1999).
52. Yang, Y. et al. Kruppel-like factor 5 controls keratinocyte migration via the integrin-linked kinase. J. Biol. Chem. 283, 18812-18820 (2008).
53. Dong, J. T., Chen, C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell. Mol. Life Sci. 66, 2691-2706 (2009).
54. Nakaya, T. et al. KLF5 regulates the integrity and oncogenicity of intestinal stem cells. Cancer Res. 74, 2882-2891 (2014).
55. Bialkowska, A. B. et al. Identification of small-molecule inhibitors of the colorectal cancer oncogene Kruppel-like factor 5 expression by ultrahighthroughput screening. Mol. Cancer Ther. 10, 2043-2051 (2011).
56. Zhi, X. et al. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Am. J. Pathol. 180, 2452-2461 (2012).
57. Zhao, D. et al. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis 33, 59-67 (2012).
58. Root, D. E. et al. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat. Methods 3, 715-719 (2006).
59. Dupont, S. et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136, 123-135 (2009).
60. Guenard, F. et al. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer. J. Hum. Genet. 54, 152-161 (2009).
61. Yu, H. et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. Natl Acad. Sci. USA 111, 285-290 (2014).
62. Zarrizi, R. et al. Deubiquitination of gamma-tubulin by BAP1 prevents chromosome instability in breast cancer cells. Cancer Res. 74, 6499-6508 (2014).
63. Lee, H. S. et al. Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis. Nat. Commun. 5, 5128 (2014).
64. Caldwell, S. A. et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 29, 2831-2842 (2010).
65. Carrano, A. C. et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1, 193-199 (1999).
66. Chen, C. et al. The amplified WWP1 gene is a potential molecular target in breast cancer. Int. J. Cancer 121, 80-87 (2007).
67. Li, Y., Zhou, Z., Chen, C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ. 15, 1941-1951 (2008).